In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Deal Statistics, Q1 2012

A look at financing, M&A, and alliance activity January–March 2012

Executive Summary

Biopharma financing totaled $3.7 billion in Q1 2012, $1 billion more than the previous quarter. A total of 22 M&As – with a potential value of $9.28 billion – were completed. Acquisitions of private biotechs structured with earn-outs were a highlight. About a quarter of the alliances involved Big Pharmas, with GlaxoSmithKline and Novartis taking the lead.

Advertisement

Related Content

Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
Setting the Stage: Qnexa and the Power of REMS
Dainippon Buys Boston Biomedical To Build On Cancer Strategy
France's Adocia Completes 2012's First Euro Biotech IPO
Verastem Joins The Public Markets With A Strong IPO
Celgene Bolsters Pipeline With Avila Acquisition
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex
Prestige Acquires 17 Glaxo OTC Brands, Enters Analgesics Market
With Lilly Out, Amylin’s Future Is Tied To Bydureon

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel